Advertisement

Cefmenoxime: Clinical Evaluation

  • Author Footnotes
    b From the Division of Infectious Diseases, Department of Medicine, Ohio State University, Columbus, Ohio.
    Robert L. Baker
    Footnotes
    b From the Division of Infectious Diseases, Department of Medicine, Ohio State University, Columbus, Ohio.
    Affiliations
    Columbus, Ohio
    Search for articles by this author
  • Author Footnotes
    b From the Division of Infectious Diseases, Department of Medicine, Ohio State University, Columbus, Ohio.
    Robert L. Perkins
    Correspondence
    Requests for reprints should be addressed to Dr. Robert L. Perkins, N-1148 University Hospitals, Columbus, Ohio 43210.
    Footnotes
    b From the Division of Infectious Diseases, Department of Medicine, Ohio State University, Columbus, Ohio.
    Affiliations
    Columbus, Ohio
    Search for articles by this author
  • Author Footnotes
    b From the Division of Infectious Diseases, Department of Medicine, Ohio State University, Columbus, Ohio.
      This paper is only available as a PDF. To read, Please Download here.
      Cefmenoxime was evaluated in an open trial consisting of 41 patients. Forty infections in 36 patients could be evaluated. Thirteen patients had pyelonephritis due to Escherichia coli (two bacteremic), Pseudomonas aeruginosa, Klebsiella pneumoniae, or Streptococcus faecalip all improved and 12 of 13 were clinically cured, but one relapse (S. faecalis) occurred at two weeks. Six-patients with cystitis due to E. coli, Citrobacter fruendii, Serratia marcescens, P. aeruginosa, or S. faecalis all improved, but relapse or reinfection, or both, occurred in five due to P. aeruginosa, S. faecalis, C. fruendii, or E. coli. Neurogenic bladder or other complications were present in five of 13 patients with pyelonephritis and five of six with cystitis. Ten patients with pneumonia and one with tracheobronchitis due to Hemophilus influenzae, S. pneumoniae, S. agalactiae, or Neisseria meningitidis all improved and seven had resolution without relapse, but P. aeruginosa emerged in two patients, one of whom died. Eight soft tissue infections due to Staphylococcus aureus, Peptococcus prevotti, Streptococcus species, or infections of mixed origin resolved in six. Sterility of blood cultures was obtained in one patient with endocarditis due to S. anginosus, but other therapy was substituted. Clinical resolution of the toxic shock syndrome and subsequent negative endocervical cultures for S. aureus occurred in one. Granulocytopenia of unverified cause in four (with less than 1,500 mm3) and two (with less than 2,000 mm3) was reversible. Headache during treatment occurred in six patients and, a possible disulfiramlike effect in three. Elevations of serum glutamic oxalacetic transaminase and alkaline phosphatase occurred in five, Coombs' positivity in two, and diarrhea in three. Clinical efficacy of Cefmenoxime was significant. Possible side effects require further study.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Fuchs PC
        • Jones RN
        • Thornsberry C
        • Barry AL
        • Gerlach EH
        • Somers HM
        Cefmenoxime (SCE-1365), a new cephalosporin: in vitro activity comparison with other antimicrobial agents, beta lactamase stability, and disk diffusion testing with tentative interpretative criteria.
        Antimicrob Agents Chemother. 1981; 20: 747-759
        • Neu HC
        • Labthavikul P
        In vitro activity and,8-lactamase stability of cefmenoxime.
        Antimicrob Agents Chemother. 1982; 22: 316-322
        • Okongi K
        • Kuno M
        • Kida M
        • Mitsuihashi S
        β-lactamase stability and antibacterial activity of cefmenoxime (SCE-1365), a novel cephalosporin.
        Antimicrob Agents Chemother. 1981; 20: 171-175
        • Acred P
        • Ryan DM
        • Sowa MA
        • Watts CM
        The in-vivo antibacterial activity of ceftazidime (Gr 20263): A comparison with other new 13-lactam antibiotics and gentamicin.
        J Antimicrob Chemother. 1981; 8: 247-255
        • Ahonkhai VI
        • Cherubin CE
        • Shulman MA
        • Bancroft U
        Comparative in vitro activities of cefmenoxime (SCE-1365) and newer cephalosporin derivatives of clinical utility.
        Antimicrob Agents Chemother. 1982; 21: 999-1002
        • Khan MY
        • Siddiqui Y
        • Simpson ML
        • Gruninger RP
        Comparative in vitro activity of cefmenoxime, cefotaxime, cefuroxime, cefoxitin, and penicillin against Neisseria gonorrhoeae.
        Antimicrob Agents Chemother. 1981; 20: 681-682
        • Stamm JM
        • Girolami RL
        • Shipkowitz NL
        • Bower RR
        Antimicrobial activity of cefmenoxime (SCE-1365).
        Antimicrob Agents Chemother. 1981; 19: 454-460
        • Tsuchiya K
        • Kondo M
        • Kida M
        • et al.
        Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities.
        Antimicrob Agents Chemother. 1981; 19: 56-65
        • Fujimura N
        • Yamamoto H
        • Yuasa K
        • Kurokama K
        Evaluation of cefmenoxime (SCE-1365) in complicated urinary tract infection.
        Chemotherapy. 1981; 29: 871-876
        • Nakamuta S
        • Kumazawa J
        • Momose S
        • et al.
        Clinical experience of cefmenoxime (SCE-1365) in chronic complicated urinary tract infection.
        Chemotherapy. 1981; 29: 886-887
        • Neu HC
        • Prince AS
        Interaction between moxalactam and alcohol.
        Lancet. 1980; 2: 1422
        • Reeves DS
        • Davies AJ
        Antabuse effect with cephalosporins.
        Lancet. 1980; 2: 540
        • Molavi A
        • Lefrock J
        • Rolston K
        • et al.
        Clinical and microbiological evaluation of cefmenoxime (abstr).
        ICAAC. 1982; : 85
        • DiCato MA
        • Ellman L
        Cephalothin-induced granulocytopenia.
        Ann Intern Med. 1975; 83: 671-672
        • Holt S
        • Khan MM
        • Orlans DA
        • Epstein EJ
        Cephalothin induced neutropenia during the treatment of bacterial endocarditis.
        Scot Med J. 1978; 23: 135-139
        • Homayouni H
        • Gross PA
        • Setia U
        • Lynch TJ
        Leukopenia due to penicillin and cephalosporin homologues.
        Arch Intern Med. 1979; 139: 827-828
        • Shansky M
        • Greenlaw CW
        Reversible acute leukopenia and cefoxitin.
        Ann Intern Med. 1980; 92: 874-875
        • Naragi S
        • Raiser M
        Nonrecurrence of cephalothin-associated granulocytopenia and thrombocytopenia.
        J Infect bis. 1982; 145: 281